Hair loss, or alopecia, can be a distressing experience, significantly affecting an individual's quality of life. Postpartum alopecia, specifically, is a common condition experienced by women after childbirth. This article aims to provide a comprehensive understanding of postpartum alopecia, its causes, and available treatment options, drawing upon research and expert recommendations.
Hair loss is not life-threatening, but it is distressing and significantly affects the patient's quality of life. Hair loss presents in various forms, ranging from the more obvious bald patches seen in alopecia areata to the subtle, diffuse thinning characteristic of telogen effluvium. When patients experience hair loss, they often seek guidance from their family physicians initially. It is crucial to determine whether the hair loss is nonscarring (noncicatricial), which is reversible, or scarring (cicatricial), which is permanent.
Hair growth occurs in three distinct phases:
Postpartum hair loss is often referred to as telogen effluvium, as it involves a greater number of hairs entering the telogen (resting) phase.
Postpartum hair loss is the excessive shedding of hair a few months after childbirth. It is a common condition caused by hormonal changes that occur during and after pregnancy. Many women notice that their hair becomes thicker and shinier during pregnancy. However, this is typically followed by a period of increased hair shedding after delivery.
Read also: Comprehensive Guide to Alopecia Areata Treatment Ointments
During pregnancy, significant hormonal changes occur, including a surge in estrogen levels. One of the first hormones to spike is human chorionic gonadotropin, or hCG. That’s the hormone your pregnancy test measured and its rising levels indicated that you were pregnant. Pregnancy also causes several other hormone levels to rise, including estrogen, progesterone, oxytocin, and prolactin. These elevated estrogen levels prolong the anagen (growth) phase of the hair cycle, leading to decreased hair loss and a fuller head of hair. In addition, your blood volume also rose during pregnancy, to as much as 50 percent greater volume than normal by your due date.
Immediately after childbirth, hormone levels, particularly estrogen and progesterone, drop rapidly. Those hormones will be almost back to normal levels within 24 hours after birth, although prolactin will stay high as long as you’re breast-feeding. Your blood volume also decreases, but its drop is more gradual. It gets back to normal a few weeks after your baby arrives. This sudden decrease causes a large number of hair follicles to enter the telogen (resting) phase simultaneously. Approximately two to four months postpartum, these hairs begin to shed, leading to noticeable hair loss.
Postpartum hair loss is a common experience, with over 90% of women experiencing some degree of hair loss after childbirth. Postpartum hair loss is a diffuse alopecia that begins about 2-4 months after delivery and lasts for about 6 months to 1 year. While the duration varies, postpartum hair shedding typically resolves within six to twelve months. Most women's hair returns to its pre-pregnancy fullness by their child's first birthday.
Postpartum hair loss is characterized by overall thinning and volume loss, rather than patchy hair loss as seen in conditions like alopecia areata. Women may notice excessive hair shedding while washing, brushing, or styling their hair. Clumps of hair may come out in the shower or while brushing.
Several factors can influence the severity and duration of postpartum hair loss, including:
Read also: Hair Loss Solutions for Black Men
The pattern of hair loss may be obvious, such as the bald patches that occur in alopecia areata, or more subtle, such as the diffuse hair loss that occurs in telogen effluvium. As with most conditions, the physician should begin the evaluation with a detailed history and physical examination. It is helpful to determine whether the hair loss is nonscarring (also called noncicatricial), which is reversible, or scarring (also called cicatricial), which is permanent. The history and physical examination are often sufficient to determine a specific etiology for hair loss. It is convenient to divide the various causes into focal (patchy) and diffuse etiologies, and proceed accordingly.
The physical examination should focus on the hair and scalp, but attention should be given to physical signs of any comorbid disease indicated by the review of systems. If only the scalp is involved, the physician should look for typical male or female pattern to determine the presence of androgenetic alopecia. Whole body hair loss is consistent with alopecia totalis. The pull test may be used to diagnose hair loss conditions. The examiner grasps approximately 40 to 60 hairs at their base using the thumb, index, and middle fingers and applies gentle traction away from the scalp. A positive result is when more than 10% of hairs (four to six) are pulled from the scalp; this implies active hair shedding and suggests a diagnosis of telogen effluvium, anagen effluvium, or alopecia areata. However, a negative test result does not necessarily exclude those conditions.
Because many conditions can cause hair loss, there are no routine tests to evaluate hair loss. If the diagnosis is not clear, laboratory testing should include a complete blood count, iron studies, copper level, liver function testing, thyroid-stimulating hormone level, and serum and urine amino acid levels.
While postpartum hair loss typically resolves on its own, several strategies can help manage the condition and promote hair regrowth:
If hair loss persists beyond one year postpartum or is accompanied by other symptoms, consulting a dermatologist is recommended. A dermatologist can assess the condition, rule out other potential causes of hair loss, and recommend appropriate treatment options.
Read also: Treating Traction Alopecia
It is important to be aware of other potential causes of hair loss, which can sometimes be confused with or coexist with postpartum alopecia:
Androgenetic alopecia is the most common form of hair loss in men and women and is a normal physiologic variant. It is most prevalent in white men, with 30%, 40%, and 50% experiencing androgenetic alopecia at 30, 40, and 50 years of age, respectively. Although this condition is less common in women, 38% of women older than 70 years may be affected. Hair thinning occurs in a sex-specific pattern. Men typically present with bitemporal thinning, thinning of the frontal and vertex scalp, or complete hair loss with residual hair at the occiput and temporal fringes. Women typically present with diffuse hair thinning of the vertex with sparing of the frontal hairline. Some women experience thinning over the lateral scalp. Treatment is based on patient preference. Topical minoxidil (2% or 5% solution) is approved for the treatment of androgenetic alopecia in men. Hair regrowth is more robust at the vertex than in the frontal area, and will take six to 12 months to improve. Treatment should continue indefinitely because hair loss reoccurs when treatment is discontinued. Finasteride (Propecia), 1 mg per day orally, is approved to treat androgenetic alopecia in men for whom topical minoxidil has been ineffective. Food and Drug Administration for the treatment of androgenetic alopecia. Both of these drugs stimulate hair regrowth in some men, but are more effective in preventing progression of hair loss.
Alopecia areata is an acute, patchy alopecia that affects up to 2% of the population with no difference between sexes. Approximately 20% of affected patients are children. The etiology is unknown, but the pathogenesis is likely autoimmune. Patients may have a single episode, or they may have remission and recurrence. Hair loss in alopecia areata occurs in three different patterns: patchy alopecia is circumscribed, oval-shaped, flesh-colored patches on any part of the body; alopecia totalis involves the entire scalp; and alopecia universalis involves the whole body. Evaluation of the scalp may reveal short vellus hairs, yellow or black dots, and broken hair shafts (which are not specific to alopecia areata). Microscopic examination of the hair follicles demonstrates exclamation mark hair (i.e., hairs that are narrower closer to the scalp and mimic an exclamation point). Treatment for adults with less than 50% of scalp involvement is intralesional triamcinolone acetonide injected intradermally using a 0.5-inch, 30-gauge needle. Maximal volume is 3 mL per session. Treatment may be repeated every four to six weeks until resolution or for a maximum of six months.
Tinea capitis is a dermatophyte infection of the hair shaft and follicles that primarily affects children. Risk factors include household exposure and exposure to contaminated hats, brushes, and barber instruments. Trichophyton tonsurans is the most common etiology in North America. Transmission occurs person-to-person or from asymptomatic carriers. Infectious fungal particles may remain viable for many months; other vectors include fallen infected hairs, animals, and fomites. Patients with tinea capitis typically present with patchy alopecia with or without scaling, although the entire scalp may be involved. Other findings include adenopathy and pruritus. Children may have an associated kerion, a painful erythematous boggy plaque, often with purulent drainage and regional lymphadenopathy. Posterior auricular lymphadenopathy may help differentiate tinea capitis from other inflammatory causes of alopecia. If the diagnosis is not clear from the history and physical examination, a skin scraping taken from the active border of the inflamed patch in a potassium hydroxide preparation can be examined microscopically for the presence of hyphae. Tinea capitis requires systemic treatment; topical antifungal agents do not penetrate hair follicles. If the causative agent is a Trichophyton species, treatment options include oral terbinafine (Lamisil), itraconazole (Sporanox), fluconazole (Diflucan), and griseofulvin. These agents have similar efficacy rates and potential adverse effects, but griseofulvin requires a longer treatment course. Griseofulvin is the preferred treatment for infections caused by Microsporum species, but definitive studies are lacking. There are limited data about empiric treatment before culture results are available. Because griseofulvin may have lower cure rates in the treatment of T.
Telogen effluvium is a nonscarring, noninflammatory alopecia of relatively sudden onset, with similar incidences between sexes and age groups. It occurs when large numbers of hairs enter the telogen phase and fall out three to five months after a physiologic or emotional stressor. The list of inciting factors is extensive and includes severe chronic illnesses, pregnancy, surgery, high fever, malnutrition, severe infections, and endocrine disorders. Patients with telogen effluvium may have symptoms of an underlying condition, but are often asymptomatic. They often notice clumps of hair coming out in the shower or in their hairbrush. Examination of the scalp in patients with telogen effluvium typically shows uniform hair thinning. The presence of erythema, scaling, or inflammation; altered or uneven hair distribution; or changes in shaft caliber, length, shape, or fragility may suggest other diagnoses. Telogen effluvium is usually self-limited and resolves within two to six months. Treatment involves eliminating the underlying cause and providing reassurance. Potentially causative medications should be discontinued, if possible.
Trichotillomania is an impulse-control disorder with a mean age of onset of approximately 13 years. Patients with this condition consciously or unconsciously pull, twist, or twirl their hair. Trichotillomania may be difficult to diagnose if the patient is not forthcoming about pulling at his or her hair. Patients typically present with frontoparietal patches of alopecia that progress posteriorly and may include the eyelashes and eyebrows. Bare patches are typical, and the hair may appear uneven, with twisted or broken off hairs. Trichotillomania may lead to problems with self-esteem and social avoidance. The optimal treatment for this condition is not known, and psychiatric referral may be indicated. Treatment options include cognitive behavior therapy and selective serotonin reuptake inhibitors, although strong evidence of a treatment effect has not been demonstrated.
Trichorrhexis nodosa occurs when hairs break secondary to trauma or because of fragile hair. It affects the proximal hair shaft, although the distal shaft may also be involved. Causative traumas include excessive brushing, heat application, tight hairstyles, trichotillomania, and conditions that cause excessive scalp scratching. Chemical traumas include harsh hair treatments (e.g., excessive use of bleach, dye, shampoo, perms, or relaxers) and excessive exposure to salt water. On examination, hairs appear to have white nodes; on closer inspection, these are shown to be fracture sites along the shaft and cortex that have split into several strands.
Anagen effluvium is abnormal diffuse hair loss (usually abrupt) during the anagen phase due to an event that impairs the mitotic or metabolic activity of the hair follicle. The incidence of anagen effluvium after chemotherapy is approximately 65%; it is most commonly associated with cyclophosphamide, nitrosoureas, and doxorubicin (Adriamycin). Other causative medications include tamoxifen, allopurinol, levodopa, bromocriptine (Parlodel), and toxins such as bismuth, arsenic, and gold. Anagen effluvium is usually reversible, with regrowth one to three months after cessation of the offending agent. Permanent alopecia is rare.
tags: #postpartum #alopecia #causes #and #treatment
